Lovenox
(Enoxaparin)ApprovedSmall molecule
SanofiEnoxaparin is a blood thinner used to prevent and treat blood clots, including those that can cause strokes, heart attacks, or pulmonary embolism (a dangerous clot in the lungs).[2] Lovenox is currently approved and in use across 49 indications[4].[1]
Lovenox is one of 971 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
49
Indications
213
Total Trials
16
Active Trials
970
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 48 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Lovenox
SanofiApproved
Singulair
AstraZenecaPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Benadryl
PParkedale
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Venous Thromboembolism19 trials
Show 16 more trials
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
Recruiting·—·N/A·NCT06689241·162 enrolled
Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
Completed·—·Phase 4·NCT04373707·1,000 enrolled
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
Terminated·MMilitary Institute od Medicine National Research Institute·Phase 2/3·NCT04558892·65 enrolled
Efficacy of Aspirin in Preventing Venous Thromboembolism
Completed·IInstituto de Seguridad y Servicios Sociales de los Trabajadores del Estado·Phase 4·NCT06635317·60 enrolled
COVID-1915 trials
Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19
Completed·—··NCT04736901·90 enrolled
Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
Unknown status·—·N/A·NCT04508439·130 enrolled
Show 12 more trials
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
Terminated·—·Phase 3·NCT04492254·219 enrolled
Prophylaxis13 trials
PROphylaxis in NOn Major Orthopaedic Surgery
Terminated·—·Phase 3·NCT02401594·3,608 enrolled
Show 10 more trials
Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Completed·—·Phase 2·NCT02706249·50 enrolled
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
Terminated·—·Phase 3·NCT00493896·27 enrolled
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Completed·—·Phase 2·NCT00908960·70 enrolled
Enoxaparin8 trials
Tirofiban and Enoxaparin in High Risk Coronary Intervention
Completed·—·Phase 4·NCT00790387·60 enrolled
Show 5 more trials
Low Molecular Weight Heparin6 trials
Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients.
Unknown status·—·Phase 4·NCT01970280·26 enrolled
81 more indications
Pulmonary Embolism6 trials
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
Terminated·—·Phase 4·NCT04558125·2 enrolled
Show 3 more trials
Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism
Completed·—·N/A·NCT00413374·40 enrolled
Knee Replacement Surgery5 trials
Total Hip Replacement5 trials
Show 2 more trials
Total Knee Arthroplasty5 trials
Show 2 more trials
Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty
Unknown status·—·Phase 4·NCT02865174·90 enrolled
Percutaneous Coronary Intervention4 trials
Total Knee Replacement4 trials
Show 1 more trial
Deep Vein Thrombosis4 trials
Total Hip Arthroplasty4 trials
Stroke3 trials
Pregnant Women3 trials
Anticoagulant3 trials
Anticoagulation3 trials
Pancreatic Cancer3 trials
Pregnancy3 trials
Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI
Unknown status·—·Phase 4·NCT02696330·150 enrolled
Venous thrombosis3 trials
Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
Unknown status·—·Phase 3·NCT04462003·100 enrolled
Acute Coronary Syndrome3 trials
Knee Surgery2 trials
Hip Replacement Surgery2 trials
Complication2 trials
Growth2 trials
Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction
Completed·—·Phase 3·NCT02672566·82 enrolled
Prevention2 trials
Brain Injury2 trials
Efficacy and Safety2 trials
Pneumonia2 trials
Acute Myocardial Infarction2 trials
TED2 trials
Pilot Study2 trials
Bariatric Surgery2 trials
Cesarean Delivery1 trial
Severe Acute Respiratory Syndrome1 trial
Cataract1 trial
Intracerebral Hemorrhage1 trial
End Stage Renal Disease (ESRD)1 trial
Echocardiography1 trial
In Vitro Fertilization1 trial
Staphylococcus Aureus1 trial
Thromboembolism1 trial
Intravenous Administration1 trial
Factor Xa Inhibitor1 trial
Ischemia1 trial
Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)
Terminated·—·Phase 4·NCT00518245·11 enrolled
Mortality1 trial
Coronary Artery Disease1 trial
Intravenous1 trial
Esophageal Cancer1 trial
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
Completed·—·Phase 3·NCT00718354·740 enrolled
Toxicity1 trial
Islet Transplantation1 trial
Atrial Fibrillation1 trial
Myocardial Infarction1 trial
Ultrasound1 trial
Catheter Infection1 trial
Ischemic stroke1 trial
Direct Oral Anticoagulants (DOACs)1 trial
Prevention of Thromboembolic Events1 trial
Thrombocytopenia1 trial
Ovarian Cancer1 trial
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
Completed·—·Phase 2·NCT03532139·24 enrolled
Abdominal Cancer Surgery1 trial
Coronary Artery Bypass1 trial
Orthopedic1 trial
Adult1 trial
Cirrhosis1 trial
Portal vein thrombosis1 trial
Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·Phase 2/3·NCT06818279·120 enrolled
Chronic Kidney Disease1 trial
Obese Patients1 trial
Treatment1 trial
Rivaroxaban1 trial
Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
Recruiting·—·Phase 4·NCT07243080·212 enrolled
Hip Fracture1 trial
Antiphospholipid Syndrome1 trial
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome
Completed·—·Phase 2·NCT01051778·60 enrolled
Impaired Renal Function1 trial
Breast Reconstruction1 trial
Regulatory
FDA Approval Timeline[5]
Jan 23, 2003
LOVENOX
NDA NDA020164
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lovenox drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Enoxaparin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]